The presentation of new data from AbbVie's ADC platform at a major oncology conference like ASCO is likely to generate positive sentiment among investors. The promising results from Phase 1 and Phase 2 studies in various cancer types could lead to increased investor confidence in AbbVie's oncology pipeline, potentially driving the stock price up in the short term.